Dr. Reddy's Laboratories (RDY) Competitors $14.20 -0.02 (-0.11%) Closing price 03:59 PM EasternExtended Trading$14.20 +0.01 (+0.07%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. ARGX, ONC, INSM, BNTX, TEVA, SMMT, GMAB, VTRS, ASND, and QGENShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S QIAGEN Dr. Reddy's Laboratories (NYSE:RDY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Do institutionals and insiders believe in RDY or ARGX? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to RDY or ARGX? In the previous week, argenex had 44 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 52 mentions for argenex and 8 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.45 beat argenex's score of 0.79 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 18 Very Positive mention(s) 4 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RDY or ARGX? Dr. Reddy's Laboratories presently has a consensus target price of $16.95, suggesting a potential upside of 19.41%. argenex has a consensus target price of $766.50, suggesting a potential upside of 7.62%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than argenex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80argenex 0 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 2 Strong Buy rating(s) 3.09 Which has more volatility & risk, RDY or ARGX? Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Is RDY or ARGX more profitable? argenex has a net margin of 40.98% compared to Dr. Reddy's Laboratories' net margin of 16.99%. argenex's return on equity of 21.06% beat Dr. Reddy's Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% argenex 40.98%21.06%18.25% Which has preferable valuation & earnings, RDY or ARGX? argenex has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.11$663M$0.6621.51argenex$2.25B19.35$833.04M$19.5036.52 Summaryargenex beats Dr. Reddy's Laboratories on 14 of the 17 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$11.86B$4.22B$5.69B$21.36BDividend Yield0.50%1.28%3.99%3.50%P/E Ratio21.5111.1979.6629.31Price / Sales3.1115.34536.5252.63Price / Cash13.767.1137.7024.03Price / Book2.874.8610.575.36Net Income$663M-$109.62M$3.27B$996.52M7 Day Performance-2.20%-0.54%0.61%0.44%1 Month Performance-3.86%21.16%5.43%3.55%1 Year Performance-13.70%33.84%50.37%12.14% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories2.8862 of 5 stars$14.20-0.1%$16.95+19.4%-14.5%$11.86B$3.81B21.5127,811News CoveragePositive NewsARGXargenex3.3527 of 5 stars$677.32+2.6%$757.88+11.9%+35.7%$40.39B$2.25B34.731,599News CoverageAnalyst ForecastAnalyst RevisionONCBeOne Medicines0.7199 of 5 stars$308.63-1.6%$330.89+7.2%N/A$34.38B$3.81B-178.4011,000Gap UpINSMInsmed3.7613 of 5 stars$128.32-2.7%$132.57+3.3%+76.4%$27.88B$363.71M-22.471,271BNTXBioNTech2.8704 of 5 stars$105.07-5.2%$135.80+29.2%+15.6%$26.66B$2.98B-65.676,772Positive NewsTEVATeva Pharmaceutical Industries3.8643 of 5 stars$18.14-1.7%$24.71+36.2%-2.9%$21.17B$16.54B-113.3836,830Trending NewsSMMTSummit Therapeutics2.1925 of 5 stars$26.27+0.3%$32.85+25.0%+86.1%$19.46B$700K-26.01110Positive NewsAnalyst ForecastAnalyst RevisionGMABGenmab A/S3.5373 of 5 stars$24.31-1.4%$37.60+54.7%-9.4%$15.81B$3.12B12.222,682News CoverageVTRSViatris1.9111 of 5 stars$10.55-0.9%$10.40-1.4%-12.5%$12.42B$14.74B-3.6432,000ASNDAscendis Pharma A/S3.3708 of 5 stars$190.37-2.0%$243.36+27.8%+39.6%$11.89B$393.54M-36.891,017Positive NewsQGENQIAGEN3.9473 of 5 stars$48.92-1.6%$49.69+1.6%+3.4%$11.06B$1.98B28.905,765Trending NewsAnalyst Revision Related Companies and Tools Related Companies argenex Alternatives BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access